The study aims to examine the protective effect of rosuvastatin on liver toxicity caused by cyclophosphamide, including tissue, inflammatory markers, and oxidative damage. Twenty-four rats were separated into three distinct groups. The first group was the untreated group, which got no therapy; the second group received just a single dose of cyclophosphamide (150 mg/kg); and the third group received rosuvastatin (20 mg/kg) every day for two weeks. On the eighth day, they also received a single dose of cyclophosphamide. On the fifteenth day, the animals were anesthetized, and the liver's tissue was taken for histology and immunohistochemical analysis. Microscopically, the cyclophosphamide group showed liver cell necrosis, severe dilation of sinusoids, proliferation of inflammatory cells, and portal vein congestion. In the cyclophosphamide + rosuvastatin (C+R) group, the pathological effects were less severe compared to the cyclophosphamide group alone. TNF-α levels were significantly elevated in the cyclophosphamide group but decreased in the rosuvastatin pretreated group compared to the cyclophosphamide group. MDA levels were elevating in the cyclophosphamide group, whereas rosuvastatin treatment significantly prevented this. This study suggests that rosuvastatin has a potential protective effect by observing the anti-inflammatory, antioxidant, and anti-apoptotic effects in the cyclophosphamide-induced liver toxicity model.